Cancers (Mar 2023)

Correlation between Imaging Markers Derived from PET/MRI and Invasive Acquired Biomarkers in Newly Diagnosed Breast Cancer

  • Kai Jannusch,
  • Ann-Kathrin Bittner,
  • Nils Martin Bruckmann,
  • Janna Morawitz,
  • Cleo Stieglitz,
  • Frederic Dietzel,
  • Harald H. Quick,
  • Hideo A. Baba,
  • Ken Herrmann,
  • Lale Umutlu,
  • Gerald Antoch,
  • Julian Kirchner,
  • Sabine Kasimir-Bauer,
  • Oliver Hoffmann

DOI
https://doi.org/10.3390/cancers15061651
Journal volume & issue
Vol. 15, no. 6
p. 1651

Abstract

Read online

Purpose: Evaluate the diagnostic potential of [18F]FDG-PET/MRI data compared with invasive acquired biomarkers in newly diagnosed early breast cancer (BC). Methods: Altogether 169 women with newly diagnosed BC were included. All underwent a breast- and whole-body [18F]FDG-PET/MRI for initial staging. A tumor-adapted volume of interest was placed in the primaries and defined bone regions on each standard uptake value (SUV)/apparent diffusion coefficient (ADC) dataset. Immunohistochemical markers, molecular subtype, tumor grading, and disseminated tumor cells (DTCs) of each patient were assessed after ultrasound-guided biopsy of the primaries and bone marrow (BM) aspiration. Correlation analysis and group comparisons were assessed. Results: A significant inverse correlation of estrogen-receptor (ER) expression and progesterone-receptor (PR) expression towards SUVmax was found (ER: r = 0.27, p 0.01; PR: r = 0.19, p 0.05). HER2-receptor expression showed no significant correlation towards SUV and ADC values. A significant positive correlation between Ki67 and SUVmax and SUVmean (r = 0.42 p 0.01; r = 0.19 p 0.05) was shown. Tumor grading significantly correlated with SUVmax and SUVmean (ρ = 0.36 and ρ = 0.39, both p’s 18F]FDG-PET/MRI may give a first impression of BC-receptor status and BC-tumor biology during initial staging by measuring glucose metabolism but cannot distinguish between DTC-positive/-negative patients and replace biopsy.

Keywords